United Therapeutics (NASDAQ:UTHR) stock soared ~12% on Wednesday after Q3 results surpassed analysts estimates.
GAAP EPS rose +43.57% Y/Y to $4.91. Total revenues grew +16% Y/Y to $516M.
"We are thrilled to report the highest quarterly revenue in our history," said United Chairperson and CEO Martine Rothblatt.
Sales of pulmonary arterial hypertension (PAH) drug Tyvaso ( an inhalation version of treprostinil) grew 57% Y/Y to $257.7M.
"We are extremely pleased to have achieved several commercial milestones in the third quarter, highlighted by Tyvaso becoming our first $1 billion annual run rate product," said United President and COO Michael Benkowitz.
Sales of Remodulin (injectable version of treprostinil) fell -9% Y/Y to $114M. Orenitram (oral version of treprostinil) generated sales of $87.5M, up +3% Y/Y.
Neuroblastoma therapy Unituxin saw a -17% Y/Y decline in sales to $46.1M. Meanwhile, sales of Adcirca fell -27% Y/Y to $10.7M.
Q3 Research and development expenses declined to $66.1M, compared to $79.2M.